Optipharm Co., Ltd.
KKRX:1537104,300.00
KRW
-45.00
(-1.04%)
ISIN
KR7153710009
Return %
Stock
S&P 500
1Y
-12.16
14.39
3Y
-40.85
81.42
5Y
-60.00
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hyun-Il Kim
- Full Time Employees
- 79
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cheongju-si South Korea
- IPO Date
- Oct 26, 2018
- Website
- optipharm.co.kr
- Similar Companies
- Business
- Optipharm Co., Ltd. is a South Korea-based biotechnology company that specializes in animal health diagnostics, bacteriophage-based antibiotic alternatives, biomedical research models, and advanced xenotransplantation therapeutics. Founded in July 2000 and headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, the company operates as an affiliate of Easy Bio Group, serving livestock producers, veterinary clinics, academic research institutions, and biopharmaceutical developers across domestic and international markets. The company categorizes its operations into five primary business divisions: Animal Disease Diagnostics, providing veterinary pathology, serology, and molecular testing services alongside rapid diagnostic test kits for livestock diseases; Bacteriophage and Feed Additives, manufacturing targeted bacteriophage products and functional feed additives, such as the ProBe-Bact line designed to control pathogens including Salmonella and Escherichia coli without conventional antibiotics; Medipig and Biomedical Models, breeding and supplying specific-pathogen-free genetically engineered miniature pigs and providing contract research organization services for preclinical efficacy and medical device evaluation; Recombinant Vaccines, leveraging insect cell-based virus-like particle platforms to develop veterinary and human prophylactic vaccines, including human papillomavirus and livestock viral disease candidates; and Xenotransplantation, developing multi-gene-edited donor pigs to provide human-compatible tissues and solid organs. In recent strategic developments, Optipharm has advanced its xenotransplantation pipeline toward human clinical trials by preparing an investigational new drug application in partnership with Hallym University Hangang Sacred Heart Hospital for porcine skin grafts in severe burn treatments, while progressing development on porcine corneal and pancreatic islet cell transplantation programs. The company has also demonstrated extended non-human primate survival milestones in preclinical xenogeneic kidney and heterotopic heart transplant models, entered a collaborative development agreement with Choong Ang Vaccine Laboratories for next-generation nanoparticle foot-and-mouth disease vaccines, and expanded overseas commercial distribution of its bacteriophage feed additives through the international marketing networks of Easy Bio and Pathway Intermediates.